HAZLET, N.J. - s4story -- In this program, experts will discuss the risk factors for, and risks of hyperkalemia, treatment goals of  acute and chronic hyperkalemia, the importance of RAASi in CKD and HF patients, the potential adverse outcomes in individuals with ESRD undergoing adequate hemodialysis with predialysis hyperkalemia,  and evidence with K+ binders in various patient populations. A multi-specialty faculty, consisting of two nephrologists, a dietician, and a primary care physician, will then discuss cardiorenal challenges faced by family physicians, including dietary recommendations to their patients with hyperkalemia. In addition, the panel will identify key cardiorenal messages for patients taking K+ binders (for hyperkalemia) and sodium-glucose cotransporter 2 (SGLT2) inhibitors which reduce the risk for hyperkalemia and significantly improve cardiorenal outcomes.

More on S For Story

• Tokenized Real-World Assets: Iguabit Brings Institutional Investment Opportunities to Brazil
• MEX Finance meluncurkan platform keuangan berbasis riset yang berfokus pada data, logika, dan efisiensi pengambilan keputusan investasi
• From MelaMed Wellness to Calmly Rooted: A New Chapter in Functional Wellness
• New Angles US Group Founder Alexander Harrington Receives Top U.S. Corporate Training Honor and Leads Asia-Pacific Engagements in Taiwan
• Jonah A. Hunt Releases New Dark Fantasy Novel - Father of Monsters

Click here for more information

CHAIR

Csaba P. Kovesdy, MD
Fred Hatch Professor of Medicine
Director, Clinical Outcomes and Clinical Trials Program in Nephrology
University of Tennessee Health Science Center
Memphis VA Medical Center
Memphis, Tennessee

FACULTY

Deborah Clegg, PhD
Vice President for Research
Texas Tech University Health Sciences Center El Paso
Professor of Internal Medicine
Paul L. Foster School of Medicine El Paso, Texas

Jay Shubrook, DO
Professor, Primary Care Department
Touro University California College of Osteopathic Medicine
Vallejo, California

Bruce Spinowitz, MD
Associate Director, Nephrology
Vice Chairman, Medicine
New York-Presbyterian Queens
Professor of Clinical Medicine
Weill Cornell Medical College
New York, New York

This educational activity is intended for primary care physicians and other clinicians managing patients at risk for, and with hyperkalemia.

More on S For Story

• UK Financial Ltd Board of Directors Establishes Official News Distribution Framework and Issues Governance Decision on Official Telegram Channels
• UK Financial Ltd Sets Official 30-Day Conversion Deadline for Three Exchange Listed Tokens Ahead of Regulated Upgrade
• New Jersey Therapy and Life Coaching Unveils Original Dan Fenelon Mural in Voorhees New Jersey Therapy Office
• Author Explodes Damning Myths about Hunger in America
• Discover the Magic of Creativity with The Balance of Brushes and Bytes

Voxmedia LLC gratefully acknowledges the educational grant provided by AstraZeneca Pharmaceuticals.

Voxmedia LLC designates this live activity for a maximum of 1.5 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Nurse practitioners may participate in this educational activity and earn a certifi cate of completion as AANP accepts AMA PRA Category 1.5 Credits™ through its reciprocity agreements.

Pre-registration is for planning purposes only and does not guarantee seating. For additional CME/CE activities visit www.CMEPlanet.com #AAFPFMX #hyperkalemia #physician #potassium #cardiorenal #diet